Fund Details
Medical Excellence Capital
Overview
Investment portfolio
13rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
TwoStep Therapeutics | Sep 2026Led | $63 MSeries A | |
Aspen Neuroscience | Nov 2025Participated | $115 MSeries C | |
Ladder Bio | Nov 2025Led | $6 MSeed | |
Pleno | Dec 2024Participated | $25 MSeries B | |
GC Therapeutics | Sep 2024Participated | $65 MSeries A | |
Truvian Sciences | Jul 2024Participated | $74 MOther Equity | |
ProJenX | Nov 2023Led | $15 MSeries A | |
Avilar Therapeutics | Feb 2023Participated | $75 MSeed | |
SonoThera | Dec 2022Participated | $61 MSeries A | |
Pleno | May 2022Led | $15 MSeries A | |
Aspen Neuroscience | May 2022Participated | $148 MSeries B | |
ProJenX | Feb 2022Led | $5 MSeed | |
TwoStep Therapeutics | Sep 2026Led | $63 MSeries A | |
Aspen Neuroscience | Nov 2025Participated | $115 MSeries C | |
Ladder Bio | Nov 2025Led | $6 MSeed | |
Pleno | Dec 2024Participated | $25 MSeries B | |
GC Therapeutics | Sep 2024Participated | $65 MSeries A | |
Truvian Sciences | Jul 2024Participated | $74 MOther Equity | |
ProJenX | Nov 2023Led | $15 MSeries A | |
Avilar Therapeutics | Feb 2023Participated | $75 MSeed | |
SonoThera | Dec 2022Participated | $61 MSeries A | |
Pleno | May 2022Led | $15 MSeries A | |
Aspen Neuroscience | May 2022Participated | $148 MSeries B | |
ProJenX | Feb 2022Led | $5 MSeed |
13 Items
13
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 2 | 1 |
| Series A | 3 | 2 |
| Series B | 0 | 3 |
| Series C+ | 0 | 1 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 2 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 1 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 1 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 1 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 2 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 13 |
| Space & Frontier Tech | 2 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 2 |
| $10M-$25M | 2 |
| $25M-$50M | 1 |
| $50M-$100M | 6 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 13 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Alexandria Venture Investments | 4 |
| ARCH Venture Partners | 3 |
| Cormorant Asset Management | 2 |
| Frazier Life Sciences | 2 |
| LifeForce Capital | 2 |
| LYFE Capital | 2 |
| M Ventures | 2 |
| NS Investment | 2 |
| OrbiMed | 2 |
| Revelation Partners | 2 |
| Section 32 | 2 |
| 120 Capital | 1 |
| 2048 Ventures | 1 |
| 7wireVentures | 1 |
| Agent Capital | 1 |
| Andreessen Horowitz | 1 |
| Astellas Venture Management | 1 |
| Axon Ventures | 1 |
| Balyasny Asset Management | 1 |
| Cercano Management | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 5 | 38% |
| Participating | 8 | 62% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 60% |
| Co-led | 2 | 40% |
Team
Brian Halak
Partner